Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.
Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.
Novavax announced promising results for its COVID-19 vaccine NVX-CoV2373 regarding cross-reactive immune responses against the Omicron variant. A two-dose regimen demonstrated effective immune responses, which were enhanced with a third booster dose, showing a 9.3-fold increase in anti-spike IgG and 19.9-fold increase in ACE2 inhibition. Immune responses in adolescents surpassed those in adults. The development of an Omicron-specific vaccine is on track for GMP manufacturing in January 2022. An investor conference call will be held today.
On December 21, 2021, Novavax (Nasdaq: NVAX) announced the administration of the first booster doses of its COVID-19 vaccine, NVX-CoV2373, in an extension of the PREVENT-19 Phase 3 clinical trial. This trial evaluates the safety and efficacy of a third booster dose administered to prior participants, at least six months after their initial vaccinations. The primary endpoint focuses on the first occurrence of PCR-confirmed COVID-19 at least seven days post-booster. NVX-CoV2373 has shown 90.4% efficacy in the PREVENT-19 trial.
WHO SAGE recommends a primary two-dose vaccination series of NVX-CoV2373 for individuals 18 and older. An additional third dose is advised for immunocompromised persons. This follows the Emergency Use Listing granted by WHO for Novavax's vaccine, branded as Nuvaxovid™ in Europe and COVOVAX™ in India. Novavax's trials have shown high efficacy, with overall efficacy rates of 89.7% in the UK trial and 90.4% in the US trial. The vaccine is anticipated to play a crucial role in the global response to COVID-19.
Novavax Announces WHO Emergency Use Listing for Nuvaxovid™
The World Health Organization has granted a second Emergency Use Listing (EUL) for Novavax's NVX-CoV2373 COVID-19 vaccine, branded as Nuvaxovid™, for individuals aged 18 and older. This follows a conditional marketing authorization from the European Commission and facilitates exports to COVAX member countries. Novavax and the Serum Institute of India have committed to supply 1.1 billion doses to COVAX. The vaccine demonstrated high efficacy in Phase 3 trials, providing a protein-based option against COVID-19 variants.
Novavax (Nasdaq: NVAX) received conditional marketing authorization from the European Commission for its Nuvaxovid™ COVID-19 vaccine. This represents the first protein-based COVID-19 vaccine approved for use in Europe, following a positive recommendation from the European Medicines Agency. An advance purchase agreement allows for up to 200 million doses through 2023, with initial supply expected in January. The vaccine demonstrated strong efficacy in pivotal Phase 3 trials, achieving 90.4% efficacy in the U.S. and Mexico, and 89.7% in the U.K.
Novavax (NASDAQ: NVAX) announced an imminent decision from the European Commission regarding the conditional marketing authorization for its COVID-19 vaccine, Nuvaxovid™ (NVX-CoV2373). This would make it the first protein-based COVID-19 vaccine available in Europe. The EMA's recommendation was based on positive clinical trial results, including a 90.4% efficacy rate in a trial with nearly 30,000 participants in the U.S. and Mexico. An advance purchase agreement for up to 200 million doses has already been established with the European Commission.
Novavax (Nasdaq: NVAX) announced that the World Health Organization (WHO) has granted Emergency Use Listing (EUL) for NVX-CoV2373, its protein-based COVID-19 vaccine, marketed as COVOVAX™ by the Serum Institute of India (SII). This EUL allows the vaccine to be distributed globally, particularly to lower-income countries via the COVAX Facility. The WHO's EUL confirms that the vaccine meets its standards for quality, safety, and efficacy. Additionally, the vaccine demonstrated high efficacy in pivotal Phase 3 trials, with 90.4% efficacy in the U.S. and Mexico trial, and 89.7% in the U.K.
Novavax, Inc. (Nasdaq: NVAX) announced the submission of a New Drug Application (NDA) for its COVID-19 vaccine, developed in partnership with Takeda, to Japan's Ministry of Health. This marks the first protein-based COVID-19 vaccine submitted for NDA in Japan. The vaccine, NVX-CoV2373, showed a strong immune response in ongoing trials and has demonstrated over 90% efficacy in pivotal Phase 3 trials. Novavax aims to start distribution in early 2022, pending approval. The company also plans to submit complete data to the U.S. FDA.
Novavax, Inc. (Nasdaq: NVAX) announced the submission of a regulatory filing to the UAE's Ministry of Health and Prevention for the emergency use of its COVID-19 vaccine, NVX-CoV2373. This vaccine demonstrated 100% protection against moderate and severe disease in pivotal U.S.-Mexico trials, with an overall efficacy of 90.4%. The company aims to deliver its vaccine globally, leveraging its partnership with the Serum Institute of India. Novavax also plans to submit a complete package to the U.S. FDA by year-end.
On Nov 24, 2021, Novavax (Nasdaq: NVAX) announced its submission for interim authorization of its COVID-19 vaccine to the Singapore Health Sciences Authority under the Pandemic Special Access Route. This filing is supported by clinical data from pivotal Phase 3 trials showing 90.4% efficacy and 100% protection against severe disease. The company aims to address obstacles in global vaccination. Novavax has also received Emergency Use Authorization in Indonesia and the Philippines and anticipates submitting a complete package to the U.S. FDA by year-end.
